Eralp Yeşim, Bavbek Sevil, Başaran Mert, Kaytan Esra, Yaman Fulya, Bilgiç Bilge, Darendeliler Emin, Onat Haluk
Department of Medical Oncology, University of Istanbul, Institute of Oncology, Turkey.
Am J Clin Oncol. 2002 Aug;25(4):418-24. doi: 10.1097/00000421-200208000-00020.
The primary objective of this study is to review the clinical characteristics of 25 patients in the adult and late adolescent age group, diagnosed and treated with small round cell tumors involving soft tissues (extraosseous Ewing sarcoma, rhabdo-myosarcoma, primitive neuroectodermal tumor, and undiffer-entiated small round cell tumors). Additionally, survival and prognostic factors influencing the outcome with multimodality treatment are evaluated. There were 19 males (76%) and 6 females (24%). The median age was 26 years (range: 15-56 years). In 9 patients (36%), the tumor was located at an extremity, whereas 16 patients (64%) had central localizations. Tumor size was larger than 10 cm in 7 patients (29.2%). Six patients (24%) had metastatic disease. Twelve patients (48%) received radiation and 16 patients (64%) underwent surgery. Among the resected tumors, 2 were resected with contaminated margins (12.5%), whereas 2 were radically resected and 12 (75%) were resected with wide margins. All patients were given a median of 4 cycles of multiagent chemotherapy (1-14 cycles). With preoperative chemotherapy, complete regression (CR) of the tumor was achieved in 6 patients (24%). In 4 patients (16%), a partial response was obtained. After the completion of multimodality treatment, 12 patients (48%) had a CR. Progression-free (PFS) and overall survival (OS) for the entire group was 25.0 +/- 10.8% at 1 year and 30.5 +/- 15.5% at 3 years, respectively. Nonmetastatic disease, wide and radical resection, and presence of CR to multimodality treatment were associated with a significantly longer PFS and OS by univariate analysis. By multivariate analysis, CR to multimodality treat-ment was the only independent predictive factor for a longer OS (p: 0.0036, relative risk [RR]: 23.6, 95% CI: 2.8; 198.7) and metastatic presentation was the only independent factor predic-tive for a shorter PFS (p: 0.017, RR. 15, 95% CI: 1.6; 141.2). Large-scale, multicenter studies are required for a better eval-uation of the nonpediatric age group with small round cell tumors.
本研究的主要目的是回顾25例成人及青少年晚期年龄组患者的临床特征,这些患者被诊断为软组织小圆细胞肿瘤(骨外尤文肉瘤、横纹肌肉瘤、原始神经外胚层肿瘤和未分化小圆细胞肿瘤)并接受了治疗。此外,还评估了多模式治疗影响预后的生存及预后因素。男性19例(76%),女性6例(24%)。中位年龄为26岁(范围:15 - 56岁)。9例患者(36%)肿瘤位于四肢,16例患者(64%)肿瘤位于身体中心部位。7例患者(29.2%)肿瘤大小大于10 cm。6例患者(24%)有转移性疾病。12例患者(48%)接受了放疗,16例患者(64%)接受了手术。在切除的肿瘤中,2例切缘有污染(12.5%),2例根治性切除,12例(75%)切缘为广泛切除。所有患者接受多药化疗的中位周期数为4个周期(1 - 14个周期)。术前化疗后,6例患者(24%)肿瘤完全消退(CR)。4例患者(16%)获得部分缓解。多模式治疗完成后,12例患者(48%)达到CR。整个组的无进展生存期(PFS)和总生存期(OS)在1年时分别为25.0±10.8%,在3年时分别为30.5±15.5%。单因素分析显示,无转移性疾病、广泛及根治性切除以及多模式治疗出现CR与显著更长的PFS和OS相关。多因素分析显示,多模式治疗出现CR是OS延长唯一的独立预测因素(p:0.0036,相对危险度[RR]:23.6,95%可信区间:2.8;198.7),转移性表现是PFS缩短唯一的独立预测因素(p:0.017,RR:15,95%可信区间:1.6;141.2)。需要进行大规模、多中心研究以更好地评估非儿童年龄组的小圆细胞肿瘤。